Nuzenio

Tipranks Gilead

Tipranks Gilead news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 19 latest news signals 3 publisher sources 100/100 entity strength

Latest news

Xenon (XENE) Receives a Buy from RBC Capital - The Globe and MailThe Globe and Mail · Sat, 08 Aug 2026 11:15:00 GMT Gilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price Target - TipRanksTipRanks · Fri, 07 Aug 2026 22:51:37 GMT Scotiabank Reaffirms Their Buy Rating on Eli Lilly & Co (LLY) - The Globe and MailThe Globe and Mail · Fri, 07 Aug 2026 12:02:00 GMT Gilead Sciences (GILD) Q2 2026 Earnings Report - Results, Call & Slides - TipRanksTipRanks · Fri, 07 Aug 2026 00:07:46 GMT Analysts Offer Insights on Healthcare Companies: InfuSystem Holdings (INFU), Arrowhead Pharmaceuticals (ARWR) and Gilead Sciences (GILD) - The Globe and MailThe Globe and Mail · Thu, 06 Aug 2026 13:22:00 GMT Gilead: Buy Rating Reaffirmed on Strong Fundamentals and HIV Franchise Momentum; $165 Price Target Maintained - TipRanksTipRanks · Wed, 05 Aug 2026 19:50:05 GMT Vertex Pharmaceuticals (VRTX) Gets a Buy from Wells Fargo - The Globe and MailThe Globe and Mail · Wed, 05 Aug 2026 13:54:00 GMT Gilead Sciences (GILD) Receives a Buy from Scotiabank - The Globe and MailThe Globe and Mail · Wed, 05 Aug 2026 13:38:00 GMT

Timeline

Sat, 08 Aug 2026 11:15:00 GMTXenon (XENE) Receives a Buy from RBC Capital - The Globe and Mail

Fri, 07 Aug 2026 22:51:37 GMTGilead: Strong HIV and Oncology Growth Underpins Reiterated Buy Rating and Unchanged $165 Price Target - TipRanks

Fri, 07 Aug 2026 12:02:00 GMTScotiabank Reaffirms Their Buy Rating on Eli Lilly & Co (LLY) - The Globe and Mail

Fri, 07 Aug 2026 00:07:46 GMTGilead Sciences (GILD) Q2 2026 Earnings Report - Results, Call & Slides - TipRanks

Thu, 06 Aug 2026 13:22:00 GMTAnalysts Offer Insights on Healthcare Companies: InfuSystem Holdings (INFU), Arrowhead Pharmaceuticals (ARWR) and Gilead Sciences (GILD) - The Globe and Mail

Wed, 05 Aug 2026 19:50:05 GMTGilead: Buy Rating Reaffirmed on Strong Fundamentals and HIV Franchise Momentum; $165 Price Target Maintained - TipRanks

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

The Globe14 live mentions Mail The Globe9 live mentions Mail9 live mentions GILD8 live mentions Receives6 live mentions Buy6 live mentions Gilead6 live mentions Gilead Sciences6 live mentions Strong HIV4 live mentions Price Target Maintained4 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tipranks Gilead.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

3 distinct publisher/source names are currently connected to this entity page.